From Hyperthyroidism to Hypothyroidism: A Detailed Analysis of Radioactive Iodine Therapy Outcomes Based on Dosage | ||
| SECI Oncology Journal | ||
| Volume 12, Issue 1, January 2024, Pages 85-87 | ||
| Abstract | ||
| Background: Hyperthyroidism, a common thyroid disorder, is often managed with radioactive iodine (RAI) therapy. However, the efficacy and outcomes of different RAI doses over time remain incompletely understood. This study aimed to evaluate the impact of various RAI doses on thyroid function in hyperthyroidism patients, assessing changes over a 12-month period post- therapy. Patients and Methods: We conducted a retrospective analysis of 303 hyperthyroidism patients who underwent RAI therapy at two medical centers. Patients were predominantly female (54.8%) with a median age of 38 years. We analyzed thyroid function at 6 and 12 months post-therapy, correlating outcomes with RAI doses ranging from 10-20 mCi. Symptoms, hormone levels, and the presence of anti-TPO antibodies were also assessed. Results: At 6 months post-RAI, 53.5% of patients developed hypothyroidism, 27.0% were euthyroid, and 19.5% remained hyperthyroid. By 12 months, 79.5% had hypothyroidism. The incidence of hypothyroidism varied with RAI dose, being highest in the 18-20 mCi group. Notably, a dose-dependent response was observed, with higher RAI doses more likely to result in hypothyroidism. Conclusions: Most Graves’ disease patients developed hypothyroidism within one year following RAI131 treatment, with higher doses associated with earlier onset hypothyroidism. RAI131 dosage and other parameters may predict hypothyroidism timing and help guide therapy individualization. | ||
| Keywords | ||
| Graves' disease; radioactive iodine therapy; Hypothyroidism | ||
|
Supplementary Files
|
||
|
Statistics Article View: 40 |
||
